Heidelberg Pharma AG (XTER:HPHA) Long-Term Capital Lease Obligation : €0.07 Mil (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Long-Term Capital Lease Obligation?

Heidelberg Pharma AG's Long-Term Capital Lease Obligation for the quarter that ended in Feb. 2024 was €0.07 Mil.

Heidelberg Pharma AG's quarterly Long-Term Capital Lease Obligation declined from Aug. 2023 (€0.10 Mil) to Nov. 2023 (€0.07 Mil) but then stayed the same from Nov. 2023 (€0.07 Mil) to Feb. 2024 (€0.07 Mil).

Heidelberg Pharma AG's annual Long-Term Capital Lease Obligation increased from Nov. 2021 (€0.08 Mil) to Nov. 2022 (€0.10 Mil) but then declined from Nov. 2022 (€0.10 Mil) to Nov. 2023 (€0.07 Mil).

Heidelberg Pharma AG Long-Term Capital Lease Obligation Historical Data

The historical data trend for Heidelberg Pharma AG's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Long-Term Capital Lease Obligation Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.10

0.08

0.10

0.07

Heidelberg Pharma AG Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.08	0.13	0.10	0.07	0.07

Heidelberg Pharma AG (XTER:HPHA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Heidelberg Pharma AG Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines